Friday, December 2, 2016 at 7 PM - 9 PM
First Unitarian Universalist Society of San Francisco
1187 Franklin St,
San Francisco, California 94109
Join Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS) for a conversation about what inspired him to found MAPS in 1986, the current state of MAPS drug development plan for MDMA-assisted psychotherapy for PTSD, and the future of psychedelic-assisted therapy. This presentation will discuss results from the Phase 2 MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD studies, and the transition to Phase 3 clinical trials.
Also discussed will be the ongoing studies for MDMA-assisted psychotherapy for anxiety associated with a terminal illness, MDMA-assisted psychotherapy for social anxiety in autistic adults, and medical marijuana for PTSD. The conversation will conclude with a discussion about regulation of MDMA-assisted psychotherapy post-approval and what that would mean for therapists, the plan to build a network of in-patient psychedelic clinic treatment centers, how the Zendo Project and harm reduction can help us prepare for a post-prohibition world, and the consequences of the presidential election on our planning.
This event is an educational program of the CIIS Center for Psychedelic Therapies and Research in collaboration with CIIS Public Programs & Performances.